key: cord-0842488-4ue6bife
authors: Danlos, F.X.; Ackermann, F.; Rohmer, J.; Roumier, M.; Marabelle, A.; Michot, J.M.
title: High levels of TNFα in patients with COVID-19 refractory to tocilizumab
date: 2021-03-20
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.01.056
sha: 888411bd04244b55f86fb2da31637bc80923217f
doc_id: 842488
cord_uid: 4ue6bife

nan

TNF-α levels were measured in serum collected from Healthy controls and COVID-19 patients before ( "baseline") and 7 days after tocilizumab. Data shown are those of all the patients treated with tocilizumab and who were able to provide a pre-treatment (baseline) and post-treatment serum (up to date serum +7). Of the 25 patients treated with tocilizumab, pre-and post-treatment serum analyzes were available for 18 patients represented according to their outcome; mortality before day 30 (left panel) and response to tocilizumab (right panel). Baseline TNF-α serum levels were significantly higher at baseline in patients who eventually died of Covid19 (left panel). Post tocilizumab TNF-α serum levels were significantly increasing in patients who did not favorably respond to tocilizumab (right panel).

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Over the last 5 years, AM and JMM have participated as principal investigators and sub-investigators of oncology clinical trials sponsored by manufacturers of anti-IL6 and anti-IL6R therapies Roche/Genentech, Sanofi/Regeneron, J&J/Janssen. AM has received honoraria from Roche/Genentech, J&J and Sanofi for consulting in the field of cancer immunotherapy. AM has received grants for oncology research from Sanofi. Gustave Roussy has received funding, grants and drug supply from Roche/Genentech, Sanofi/Regeneron, Janssen for running clinical trials or research projects in oncology. FXD, FA, JR and MR have no conflict of interest to disclose.

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Effective treatment of severe COVID-19 patients with tocilizumab

Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19

An inflammatory cytokine signature predicts COVID-19 severity and survival

A minimal common outcome measure set for COVID-19 clinical research

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Acknowledgements: we would like to thank the following collaborators for their effort during this